Safety and Efficacy of Anti-Oxidants and Anti-inflammatory Agents in Glaucoma and Diabetic Retinopathy

Exclusion Criteria

• •1. Comorbidity with other severe or chronic eye conditions that in the judgment of the investigator will interfere with study assignment, such as age-related macular degeneration, macular dystrophy, retinopathy from systemic diseases, marked ocular media opacities that obscure retinal imaging, etc.
• •2. BCVA \<20/200
• •3. Concurrent conjunctivitis, keratitis or uveitis
• •4. History of penetrating ocular trauma.
• •5. Subject uncooperativeness that restricts adequate examination of IOP, ocular fundus or anterior chamber.
• •6. Has a condition or history that, in the opinion of the investigator, may interfere significantly with the subject's participation in the study.
• •7. A woman who is pregnant, nursing an infant, or planning a pregnancy
• •8. Has a known adverse reaction and/or sensitivity to the study drug or its compound.
• •a. Including: alpha lipoic acid, citicoline, Co-enzyme Q-10, Ginkgo biloba extract, grape seed extract, N-acetyl-cysteine, curcumin, green tea extract, and bilberry extract.
• •9. Currently enrolled in an investigational drug study or has used an investigational drug within 30 days prior to Visit 1.
• •10. Is planning on having surgery at any time throughout the study duration (90 days from initiation)
• •11. Is currently receiving chemotherapy
• •12. Has a history of diabetes mellitus, seizure(s), bleeding disorder(s)
• •13. Has a history of uncontrolled hypertension (≥180 systolic or ≥110 diastolic on two successive measures)
• •14. Has a history of any radiation around the eyes
• •15. Currently using anticoagulant/antiplatelet drugs (patients on coumadin, clopidogral (Plavix), and plasugrel (Effient) will be excluded but that patients taking aspirin will be allowed)
• •16. Unwilling or unable to cease using other anti-oxidative agents or drugs.
• •17. Dilated pupil diameter less than 5 millimeters
• •18. Fluorescein drop administration within 8 hours before imaging
• •19. History of cataract surgery in the 3 months prior to imaging
• •20. History of any other intraocular surgery within 4 months prior to enrollment
• •21. Corticosteroid or immunosuppressive therapy within 6-months prior to imaging
• •22. Lens opacity ≥grade 3 on ARLNS on standard photographs (Appendix 6)
• •23. History of vitrectomy
• •24. Monocular patients